AZD0516
AZD0516 is a first-in-class antibody-drug conjugate (ADC) targeting six-transmembrane epithelial antigen of the prostate-2 (STEAP2). The anti-STEAP2 monoclonal antibody (mAb) is conjugated via interchain cysteines to a maleimide-reactive, β-glucuronidase-cleavable linker bearing the topoisomerase 1 inhibitor, Exatecan (HY-13631). AZD0516 can be used for the study of prostate cancer[1].
Product Specifications
UNSPSC
12352211
Target
Antibody-Drug Conjugates (ADCs) ; Topoisomerase
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
95.82
Smiles
[AZD0516]
References & Citations
[1]1158-Preclinical characterization of AZD0516, a novel STEAP2 antibody-drug conjugate (ADC) for the treatment of prostate cancer. AACR Annual Meeting 2025 Itinerary Planner Home.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
TRC-B519545-25MG 25 mg
Bisphenol F Bis(2-chloro-1-propanol) Ether( Mixture of Diastereomers)
Sign In for Pricing
View Details 
MBS6300089-01 0.1 mL
FRAT2, CT (FRAT2, GSK-3-binding protein FRAT2, Frequently rearranged in advanced T-cell lymphomas 2) (MaxLight 650)
Sign In for Pricing
View Details 
MBS6300089-02 5x 0.1 mL
FRAT2, CT (FRAT2, GSK-3-binding protein FRAT2, Frequently rearranged in advanced T-cell lymphomas 2) (MaxLight 650)
Sign In for Pricing
View Details orb1651389-01 20 µg
Recombinant Rat Basic leucine zipper transcriptional factor ATF-like 3 (Batf3)
Sign In for Pricing
View Details orb1651389-02 100 µg
Recombinant Rat Basic leucine zipper transcriptional factor ATF-like 3 (Batf3)
Sign In for Pricing
View Details